Otsuka to develop Sativex in US with GW; deal terminated
Executive Summary
Otsuka Pharmaceutical has licensed exclusive US rights from GW Pharmaceuticals PLC (cannabis-based therapeutics for cancer and CNS disorders) to develop and market Sativex (9-tetrahydrocannabinol and cannabidiol), GW's lead cannabinoid drug candidate for pain in cancer patients.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice